🇺🇸 uracil-tegafur in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 18

Most-reported reactions

1. Diarrhoea — 4 reports (22.22%)
2. Drug Resistance — 3 reports (16.67%)
3. Dysaesthesia Pharynx — 3 reports (16.67%)
4. Dehydration — 2 reports (11.11%)
5. Abdominal Pain — 1 report (5.56%)
6. Abdominal Pain Upper — 1 report (5.56%)
7. Activated Partial Thromboplastin Time Shortened — 1 report (5.56%)
8. Acute Myeloid Leukaemia — 1 report (5.56%)
9. Acute Respiratory Distress Syndrome — 1 report (5.56%)
10. Anorexia — 1 report (5.56%)

Source database →

Frequently asked questions

Is uracil-tegafur approved in United States?

uracil-tegafur does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for uracil-tegafur in United States?

Urological Oncology Council of Northern Tokyo is the originator. The local marketing authorisation holder may differ — check the official source linked above.